Drug-metabolizing enzymes and transporters: Expression in the human prostate and roles in prostate drug disposition

Journal of Andrology

Volumn 27, Issue 2, 2006, Pages 138-150

  Obligacion, Regina ^a   Murray, Michael ^a   Ramzan, Iqbal ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTINEOPLASTIC AGENT; ARYLAMINE ACETYLTRANSFERASE; BICALUTAMIDE; CARRIER PROTEIN; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DOXAZOSIN; DRUG METABOLIZING ENZYME; DUTASTERIDE; FINASTERIDE; FLUTAMIDE; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; INDORAMIN; MULTIDRUG RESISTANCE PROTEIN; NILUTAMIDE; PRAZOSIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; UNINDEXED DRUG;

CHEMICAL CARCINOGENESIS; DRUG DISPOSITION; DRUG MECHANISM; DRUG OXIDATION; DRUG RECEPTOR BINDING; DRUG TRANSFORMATION; HUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; CARRIER PROTEINS; CYTOCHROME P-450 ENZYME SYSTEM; GENE EXPRESSION REGULATION; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; TRANSFERASES;

EID: 33644530713     PISSN: 01963635     EISSN: None     Source Type: Journal    
DOI: 10.2164/jandrol.05113     Document Type: Review

References (140)

1. Agundez J, Martinez C, Olivera M, Gallardo L, Ladero J, Rosado C, Prados J, Rodriguez-Molina J. Expression in human prostate of drug-and carcinogen-metabolizing enzymes: association with prostate cancer risk. Br J Cancer. 1998;78:1361-1367.
2. Albert C, Vallee M, Beaudry G, Belanger A, Hum DW. The monkey and human undine diphosphate-glucuronosyltransferase UGT1A9, expressed in steroid target tissues, are estrogen-conjugating enzymes. Endocrinology. 1999;140:3292-3302.
3. Ambudkar S, Kimchi-Sarfaty C, Sauna Z, Gottesman M. P-glycoprotein: from genomics to mechanisms. Oncogene. 2003;22:7468-7485.
4. Ando Y, Shimizu T, Nakamura K, Musiroda T, Nakagawa T, Kodama T, Kamataki T. Potent and non-specific inhibition of cytochrome P450 by JM216, a new oral platinum agent. Br J Cancer. 1998;78:1170-1174.
5. Andriole G, Kirby R. Safety and tolerability of the dual 5α-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol. 2003;44:82-88.
6. Barbier O, Lapointe H, El Alfy M, Hum DW, Belanger A. Cellular localization of uridine diphosphoglucuronosyltransferase 2B enzymes in the human prostate by in situ hybridization and immunohistochemistry. J Clin Endocrinol Metab. 2000;85:4819-4826.
7. Beaulieu M, Levesque E, Hum DW, Belanger A. Isolation and characterization of a novel cDNA encoding a human UDP-glucuronosyltransferase active on C19 steroids. J Biol Chem. 1996;271:22855-22862.
8. Belanger G, Beaulieu M, Marcotte B, Levesque E, Guillemette C, Hum DW, Belanger A. Expression of transcripts encoding steroid UDP- glucuronosyltransferases in human prostate hyperplastic tissue and the LNCaP cell line. Mol Cell Endocrinol. 1995;113:165-173.
9. Berson A, Wolf C, Chachaty C, Fisch C, Fau D, Eugene D, Loeper J, Gauthier J, Beaune P, Pompon D. Metabolic activation of nitroaromatic antiandrogen flutamide by rat and human cytochromes P-450, including forms belonging to the 3A and 1A subfamilies. J Pharmacol Exp Ther. 1993;265:366-372.
10. Boocock D, Brown K, Gibbs A, Sanchez E, Turteltaub K, White I. Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis. 2002;23:1897-1901.
11. Borst P, Elferink R. Mammalian ABC transporters in health and disease. Annu Rev Biochem. 2002;71:537-592.
12. Boyle P, Roehrborn C, Harkaway R, Logie J, de la Rosette J, Emberton M. 5-alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery. Eur Urol. 2004;45:620-627.
13. Bruggemann E, Currier S, Gottesman M, Pastan I. Characterization of the azidopine and vinblastine binding site of P-glycoprotein. J Biol Chem. 1992;267:21020-21026.
14. Carnell DM, Smith RE, Daley FM, Barber PR, Hoskin PJ, Wilson GD, Murray GI, Everett SA. Target validation of cytochrome P450 CYP1B1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue. Int J Radiat Oncol Biol Phys. 2004;58:500-509.
15. Chang T, Yu L, Goldstein J, Waxman D. Identification of the polymorphically expressed CYP2C19 and wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics. 1997;7:211-221.
16. Chen Z, Lee K, Walther S, Raftogianis R, Kuwano M, Zeng H, Kruh G. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002;62:3144-3150.
17. Chen Z, Robey R, Belinsky M, Shchaveleva I, Ren X, Sugimoto Y, Ross D, Bates S, Kruh G. Transport of methotrexate, methotrexate polyglutamates, and 17β-estradiol 17-(β-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res. 2003;63:4048-4054.
18. Chetcuti A, Margan S, Mann S, Russell P, Handelsman D, Rogers J, Dong Q. Identification of differentially expressed genes in organ-confined prostate cancer by gene expression array. Prostate. 2001;47:132-140.
19. Chouinard S, Pelletier G, Belanger A, Barbier O. Cellular specific expression of the androgen-conjugating enzymes UGT2B15 and UGT2B17 in the human prostate epithelium. Endocrinol Res. 2004;30:717-725.
20. Chu D, Chuang C, Fu J, Huang H, Tseng C, Sun C. The use of real-time quantitative polymerase chain reaction to detect hypermethylation of the CpG islands in the promoter region flanking the GSTP1 gene to diagnose prostate carcinoma. J Urol. 2002;167:1854-1858.
21. Cockshott I. Bicalutamide, clinical pharmacokinetics and metabolism. Clin Pharmacokinet. 2004;43:855-878.
22. Cookson MS, Reuter VE, Linkov I, Fair W. Glutathione S-transferase pi (GST-pi) class expression by immunohistochemistry in benign and malignant prostate tissue. J Urol. 1997;157:673-676.
23. Cooray H, Janvilisri T, van Veen H, Hladky S, Barrand M. Interaction of the breast cancer resistance protein with plant polyphenols. Biochem Biophys Res Commun. 2004;317:269-275.
24. Cresteil T, Monsarrat B, Alvinerie P, Treluyer M, Veira I, Wright M. Taxol metabolism by human liver microsomes: identification of cytochrome P450 involved in its biotransformation. Cancer Res. 1994;54:386-392.
25. Cresteil T, Monsarrat B, Dubois J, Sonnier M, Alvinerie P, Gueritte F. Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship. Drug Metab Dispos. 2002;30:438-445.
26. Crewe H, Notley L, Wunsch R, Lennard M, Gillam E. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002;30:869-874.
27. Cui L, Takahashi S, Tada M, Kato K, Yamada Y, Kohri K, Shirai T. Immunohistochemical detection of carcinogen-DNA adducts in normal human prostate tissues transplanted into the subcutis of athymic nude mice: results with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and 3,2′-dimethyl- 4-aminobiphenyl (DMAB) and relation to cytochrome P450s and N-acetyltransferase activity. Jpn J Cancer Res. 2000;91:52-58.
28. Dagher R, Li N, Abraham S, Rahman A, Sridhara R, Pazdur R. Approval summary: docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. Clin Cancer Res. 2004;10:8147-8151.
29. Daigo S, Takahashi Y, Fujieda M, Ariyoshi N, Yamazaki H, Koizumi W, Tanabe S, Saigenji K, Nagayama S, Ikeda K, Nishioka Y, Kamataki T. A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics. 2002;12:299-306.
30. Dearnaley D. Current issues in cancer: cancer of the prostate. Br Med J. 1994;308:780-784.
31. Denmeade S, Isaacs J. Development of prostate cancer treatment. Prostate. 2004;58:211-224.
32. Di Ilio C, Aceto A, Bucciarelli T, Angelucci S, Felaco M, Grilli A, Federici G. Glutathione transferase isoenzymes from human prostate. Biochem J. 1990;271:481-485.
33. DiPaola RS, Chenven ES, Shih WJ, Lin Y, Amenta P, Goodin S, Shumate A, Capanna T, Cardiella M, Cummings KB, Aisner J, Todd MB. Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma. Cancer. 2001;92:2065-2071.
34. Domanski T, Finta C, Halpert J, Zaphiropoulos P. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol. 2001;59:386-392.
35. Doyle L, Ross D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene. 2003;22:7340-7358.
36. Elek J, Park KH, Narayanan R. Microarray-based expression profiling in prostate tumors. In Vivo. 2000;14:173-182.
37. El Etreby M, Liang Y, Lewis R. Induction of apoptosis by mifepristone and tamoxifen in human LNCaP prostate cancer cells in culture. Prostate. 2000;43:31-42.
38. Febbo P, Kantoff P, Giovannucci E, Brown M, Chang G, Hennekens C. Stampfer M. Debrisoquine hydroxylase (CYP2D6) and prostate cancer. Cancer Epidem Biomar. 1998;7:1075-1078.
39. Ferguson L. Meat consumption, cancer risk and population groups within New Zealand. Mutat Res. 2002;506:215-224.
40. Finnström N, Bjelfman C, Söderström T, Smith G, Egevad L, Norlen B, Wolf C, Rane A. Detection of cytochrome P450 mRNA transcripts in prostate samples by RT-PCR. Eur J Clin Invest. 2001;31:880-886.
41. Fontana R, Lown K, Paine M, Fortlage L, Santella R, Felton J, Knize M, Greenberg A, Watkins P. Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers. Gastroenterology. 1999;117:89-98.
42. Garrigues A, Loiseau N, Delaforge M, Ferte J, Garrigos M, Andre F, Orlowski S. Characterization of two pharmacophores on the multidrug transporter p-glycoprotein. Mol Pharmacol. 2002;62:1288-1298.
43. Gonzalez F, Gelboin H. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev. 1994;26:165-183.
44. Gonzalgo M, Pavlovich C, Lee S, Nelson W. Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin Cancer Res. 2002;9:2673-2677.
45. Grzywacz M, Yang J, Hait W. Effect of the multidrug resistance protein on the transport of the antiandrogen flutamide. Cancer Res. 2003;63:2492-2498.
46. Gurtoo H, Marinello A, Struck R, Pahl B, Dahms R. Studies on the mechanism of denaturation of cytochrome P450 by cyclophosphamide and its metabolites. J Biol Chem. 1981;256:11691-11701.
47. Hagenauer B, Salamon A, Thalhammer T, Kunert O, Haslinger E, Klinger P, Senderowicz A, Sausville E, Jager W. In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes; involvement of UDP glucuronosyltransferases 1A1 and 1A9. Drug Metab Dispos. 2001;29:407-414.
48. Hamasaki T, Inatomi H, Katoh T, Aono H, Ikuyama T, Muratani T, Matsumoto T. N-acetyltransferase-2 gene polymorphism as a possible biomarker for prostate cancer in Japanese men. Int J Urol. 2003;10:167-173.
49. Harden S, Guo Z, Epstein J, Sidransky D. Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma. J Urol. 2003;169:1138-1142.
50. Harris J, Rahman A, Kim B, Guenguerich F, Collins J. Metabolism of taxol by hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 1994;54:4026-4035.
51. Hayer-Zillgen M, Bruss M, Bonisch H. Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002;136:829-836.
52. Heikinheimo O. Clinical pharmacokinetics of mifepristone. Clin Pharmacokinet. 1997;33:7-17.
53. Huang Z, Roy P, Waxman D. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol. 2000;59:961-972.
54. Huskey S, Dean D, Miller R, Rasmusson G, Chiu S-HL. Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride. Drug Metab Dispos. 1995;23:1126-1135.
55. Imaoka S, Yoneda Y, Sugimoto T, Hiroi T, Yamamoto K, Nakatani T, Funae Y. CYP4B1 is a possible risk factor for bladder cancer in humans. Biochem Biophys Res Commun. 2000;277:776-780.
56. Ito S, Ieiri I, Tanabe M, Suzuki A, Higuchi S, Otsubo K. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics. 2001;11:175-184.
57. Jang G, Benet L. Antiprogestin pharmacodynamics, pharmacokinetics, and metabolism: implications for their long-term use. J Pharmacokinet Biopharm. 1997;25:647-672.
58. Jang G, Wrighton S, Benet L. Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes. Biochem Pharmacol. 1996;52:753-761.
59. Kajita J, Kuwabara T, Kobayashi H, Kobayashi S. CYP 3A4 is mainly responsible for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metab Dispos. 2000;28:1121-1127.
60. Kamimura S, Oishi S, Matsushima H, Watanabe T, Higuchi S, Hall M, Wood S, Chasseaud L. Identification of cytochrome P450 isozymes involved in metabolism of the alpha 1-adrenoceptor blocker tamsulosin in human liver microsomes. Xenobiotica. 1998;28:909-922.
61. Kawai K, Sakurai M, Sakai T, Misaki M, Kusano I, Shiraishi T, Yatani R. Demonstration of MDR1 P-glycoprotein isoform expression in benign and malignant human prostate cells by isoform-specific monoclonal antibodies. Cancer Lett. 2000;150:147-153.
62. Kawashiro T, Yamashita K, Zhao X, Koyama E, Tani M, Chiba K, Ishizaki T. A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998;286:1294-1300.
63. Keshava C, McCanlies E, Weston A. CYP3A4 polymorphisms-potential risk factors for breast and prostate cancer: a HuGE review. Am J Epidemiol. 2004;160:825-841.
64. Khan K, He Y. Differential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: selective inactivation of P450 3A4. Drug Metab Dispos. 2002;30:985-990.
65. Kim S, Suzuki N, Santosh Laxmi Y, Rieger R, Shibutani S. Alpha-hydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes. Chem Res Toxicol. 2003;16:1138-1144.
66. Kinoshita Y, Singh A, Rovito P, Wang C, Haas G. Double primary cancers of the prostate and bladder: a literature review. Clin Prostate Cancer. 2004;3:83-86.
67. Klose TS, Blaisdell JA, Goldstein JA. Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J Biochem Mol Toxicol. 1999;13:289-295.
68. Klus GT, Nakamura J, Li JS, Ling YZ, Son C, Kemppainen JA, Wilson EM, Brodie AM. Growth inhibition of human prostate cells in vitro by novel inhibitors of andogen synthesis. Cancer Res. 1996;56:4956-4964.
69. Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O, Nuessler A, Neuhaus P, Eichelbaum M, Zanger U, Wojnowski L. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos. 2002;30:1108-1114.
70. Komatsu T, Yamazaki H, Shimada N, Nakajima M, Yokoi T. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000;28:1457-1463.
71. Krishna D, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet. 1994;26:144-160.
72. Kumar G, Walle U, Walle T. Cytochrome P450 3A mediated human liver microsomal taxol 6α-hydroxylation. J Pharmacol Exp Ther. 1994;268:1160-1165.
73. Lang T, Hitzl M, Burk O, Mornhinweg E, Keil A, Kerb R, Klein K, Zanger U, Eichelbaum M, Fromm M. Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver. Pharmacogenetics. 2004;14:155-164.
74. Lee K, Belinsky M, Bell D, Testa J, Kruh G. Isolation of MOAT-B, a widely expressed multidrug resistance-associated protein/canalicular multispecific organic anion transporter-related transporter. Cancer Res. 1998;58:2741-2747.
75. Lee K, Klein-Szanto J, Kruh G. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J Nat Cancer Inst. 2000;92:1934-1940.
76. Lee W, Morton R, Epstein J, Brooks J, Campbell P, Bova G, Shsieh W, Isaacs E, Nelson W. Cytidine methylation of regulatory sequences near the π-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A. 1994;91:11733-11737.
77. Li M, Ittmann MM, Rowley DR, Knowlton AA, Vaid AK, Epner DE. Glutathione S-transferase pi is upregulated in the stromal compartment of hormone independent prostate cancer. Prostate. 2003;56:98-105.
78. Lin X, Tascillar M, Lee W, Vles W, Lee B, Veeraswamy R, Asgari K, Freije D, Van Rees B, Gage W, Bova G, Isaacs W, Brooks J, DeWeese T, De Marzo A, Nelson W. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol. 2001;159:1815-1826.
79. Long L, Dolan M. Role of cytochrome P450 isoenzymes in metabolism of O(6)benzyl-guanine: implications for dacarbazine activation. Clin Cancer Res. 2001;7:4239-4244.
80. Ly L, Zhao X, Holloway L, Feldman D. Liarazole acts synergistically with 1 alpha, 25-dihydroxyvitamin D3 to inhibit growth of DU145 human prostate cells by blocking 24-hydroxylase activity. Endocrinology. 1999;140:2071-2076.
81. Marre F, Sanderink G, de Sousa G, Gaillard C, Martinet M, Rahmani R. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res. 1996;56:1296-1302.
82. May-Manke A, Kroemer H, Hempel G, Bohnenstengel F, Hohenlochter B, Blaschke G, Boos J. Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N-dechloroethylation of trofosfamide. Cancer Chemother Pharmacol. 1999;44:327-334.
83. Montironi R, Mazzucchelli R, Pomante R, Thompson D, da Silva V, Vaught L, Bartels P. Immunohistochemical expression of pi class glutathione S-transferase in the basal cell layer of benign prostate tissue following chronic treatment with finasteride. J Clin Pathol. 1999;52:350-354.
84. Montironi R, Mazzucchelli R, Stramazzotti D, Pomante R, Thompson D, Bartels PH. Expression of pi-class glutathione S-transferase: two populations of high grade prostatic intraepithelial neoplasia with different relations to carcinoma. Mol Pathol 2000;53:122-128.
85. Moskaluk CA, Duray PH, Cowan KH, Linehan M, Merino MJ. Immunohistochemical expression of pi-class glutathione S-transferase is down-regulated in adenocarcinoma of the prostate. Cancer. 1997;79:1595-1599.
86. Murata M, Watanabe M, Yamanaka M, Kubota Y, Ito H, Nagao M, Katoh T, Kamataki J, Kawamura J, Yatani R, Shiraishi T. Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP 2E1, glutathione S-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population. Cancer Lett. 2001;165:171-177.
87. Murray G. The role of cytochrome P450 in tumour development and progression and its potential in therapy. J Pathol. 2000;1992:419-426.
88. Murray G, Shaw D, Weaver R, McKay J, Ewen S, Melvin W, Burke M. Cytochrome P450 expression in oesophageal cancer. Gut. 1994a;35:599-603.
89. Murray G, Taylor M, Burke M, Melvin W. Enhanced expression of cytochrome P450 in stomach cancer. Br J Cancer. 1998;77:1040-1044.
90. Murray G, Taylor V, McKay J, Weaver R, Ewen S, Melvin W, Burke M. The immunohistochemical localization of drug-metabolizing enzymes in prostate cancer. J Pathol. 1995;177:147-152.
91. Murray M, Butler A, Stupans I. Competitive inhibition of human liver microsomal cytochrome P450 3A-dependent steroid 6 beta-hydroxylation activity by cyclophosphamide and ifosfamide in vitro. J Pharmacol Exp Ther. 1994b;270:645-649.
92. Muskhelishvili L, Thompson PA, Kusewitt DF, Wang C, Kadlubar FF. In situ hybridization and immunohistochemical analysis of cytochrome P450 1B1 expression in human normal tissues. J Histochem Cytochem. 2001;49:229-236.
93. Nakajima T, Wang R, Nimura Y, Pin Y, He M, Vainto H, Murayama N, Aoyama T, Iida F. Expression of cytochrome P450s and glutathione S-transferase in human oesophagus with squamous-cell carcinomas. Cardnogenesis. 1996;17:1477-1481.
94. Nakayama M, Bennett C, Hicks J, Epstein J, Platz E, Nelson W, De Marzo A. Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am J Pathol. 2003:923-933.
95. Nakazato H, Suzuki K, Matsui H, Koike H, Okugi H, Ohtake N, Takei T, Nakata S, Hasumi M, Ito K, Kurokawa K, Yamanaka H. Association of genetic polymorphisms of glutathione-S-transferase genes (GSTM1, GSTT1 and GSTP1) with familial prostate cancer risk in Japanese population. Anticancer Res. 2003;23:2897-2902.
96. Nelson C, Kidd L, Sauvageot J, Isaacs W, De Marzo A, Groopman J, Nelson W, Kensler T. Protection against 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b] pyridine cytotoxicity and DNA adduct formation in human prostate by glutathione S-transferase P1. Cancer Res. 2001;61:103-109.
97. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 1996;6:1-42.
98. Nishimura M, Yaguti H, Yoshitsugu H, Naito S, Satoh T. Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2003;123:369-375.
99. Nooter K, Westerman AM, Flens MJ, Zaman GJ, Scheper RJ, van Wingerden KE, Burger H, Oostrum R, Boersma T, Sonneveld P. Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res. 1995;1:1301-1310.
100. Ozvegy C, Litman T, Szakacs G, Nagy Z, Bates S, Varadi A, Sarkadi B. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001;285:111-117.
101. Parsons JK, Nelson CP, Gage WR, Nelson WG, Kensler TW, De Marzo AM. GSTA1 expression in normal, preneoplastic, and neoplastic human prostate tissue. Prostate. 2001;49:30-37.
102. Pierce D. A review of the clinical pharmacokinetics and metabolism of the alpha 1-adrenoceptor antagonist indoramin. Xenobiotica. 1990;20:1357-1367.
103. Pont A, Williams P, Azhar S, Reitz R, Bochra C, Smith E. Ketoconazole blocks testosterone synthesis. Arch Intern Med. 1982;142:2137-2140.
104. Rahman A, Korzekwa K, Grogan J, Gonzalez F, Harris J. Selective biotransformation of Taxol to 6α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 1994;54:5543-5546.
105. Ramzi D, Li N, Abraham S, Rahman A, Sridhara R, Pazdur R. Approval summary: docetaxel in combination with prednisone for the treatment of androgen-independent hormone refractory prostate cancer. Clin Cancer Res. 2004;10:8147-8151.
106. Rebbeck T, Jaffe J, Walker A, Wein A, Malkowicz S. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Nat Cancer Inst. 1998;90:1225-1229.
107. Reid J, Kuffel M, Miller J, Rios R, Ames M. Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. Clin Cancer Res. 1999;5:2192-2197.
108. Reidy G, Murray M. In vitro inhibition of hepatic steroid hydroxylation by tamoxifen, a series of tamoxifen analogues and related compounds. Biochem Pharmacol. 1989;38:195-199.
109. Relling M, Nemec J, Schuetz E, Schuetz J, Gonzalez F, Korzekwa K. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol. 1994;45:352-358.
110. Rocchi E, Khodjakov A, Volk EL, Yang CH, Litman T, Bates SE, Schneider E. The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane. Biochem Biophys Res Commun. 2000;271:42-46.
111. Rochat B, Morsman J, Murray G, Figg W, McLeod H. Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation. J Pharmacol Exp Ther. 2001;296:537-541.
112. Saito S, Iida A, Sekine A, Miura Y, Ogawa C, Kawauchi S, Higuchi S, Nakamura Y. Identification of 779 genetic variations in eight genes encoding members of the ATP-binding cassette, subfamily C (ABCC/MRP/CFTR). J Hum Genet. 2002;47:147-171.
113. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics. 2003;4:397-410.
114. Santourlidis S, Florl A, Ackermann R, Wirtz H, Schulz W. High frequency of alterations in DNA methylation in adenocarcinoma of the prostate. Prostate. 1999;39:166-174.
115. Schummer B, Siegsmund M, Steidler A, Toktomambetova L, Kohrmann KU, Alken P. Expression of the gene for the multidrug resistance-associated protein in human prostate tissue. Urol Res. 1999;27:164-168.
116. Shapiro A, Ling V. The mechanism of ATP-dependent multidrug transport by P-glycoprotein. Acta Physiol Scand. 1998;643:227-234.
117. Shet M, McPhaul M, Fisher C, Stallings N, Estabrook R. Metabolism of the antiandrogenic drug (flutamide) by human CYP1A2. Drug Metab Dispos. 1997;25:1298-1303.
118. Shirakawa K, Takara K, Tanigawara Y, Aoyama N, Kasuga M, Komada F, Sakaeda T, Okumura K. Interaction of docetaxel ("Taxotere") with human P-glycoprotein. Jpn J Cancer Res. 1999;90:1380-1386.
119. Shou M, Martinet M, Korzekwa K, Krausz K, Gonzalez F, Gelboin H. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics. 1998;8:391-401.
120. Sladek N. Metabolism of oxazaphosphorines. Pharmacol Ther. 1988;37:301-355.
121. Song L, Coghlan M, Gelmann E. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. Mol Endocrinol. 2004;18:70-85.
122. Sterling KJ, Cutroneo K. Constitutive and inducible expression of cytochromes P450 (CYP1A1 and CYP1A2) in normal prostate and prostate cancer cells. J Cell Biochem. 2004;91:423-429.
123. Sugawara I, Akiyama S, Scheper RJ, Itoyama S. Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP. Cancer Lett. 1997;112:23-31.
124. Sullivan GF, Amenta PS, Villanueva JD, Alvarez CJ, Yang JM, Hait WN. The expression of drug resistance gene products during the progression of human prostate cancer. Clin Cancer Res. 1998;4:1393-1403.
125. Sundberg AG, Nilsson R, Appelkvist EL, Dallner G. Immunohistochemical localization of alpha and pi class glutathione transferases in normal human tissues. Pharmacol Toxicol. 1993;72:321-331.
126. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K. Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002;70:1491-1500.
127. Tew K, Clapper M, Greenberg R, Weese J, Hoffman S, Smith T. Glutathione S-transferases in human prostate. Biochim Biophys Acta. 1987;926:8-15.
128. Turesky RJ, Lang NP, Butler MA, Teitel CH, Kadlubar FF. Metabolic activation of carcinogenic heterocyclic aromatic amines by human liver and colon. Carcinogenesis. 1991;12:1839-1845.
129. Uchiumi T, Hinoshita E, Haga S, Nakamura T, Tanaka T, Toh S, Furukawa M, Kawabe T, Wada M, Kagotani K, Okumura K, Kohno K, Akiyama S, Kuwano M. Isolation of a novel human canalicular multispecific organic anion transporter, cMOAT2/MRP3, and its expression in cisplatin-resistant cancer cells with decreased ATP-dependent drug transport. Biochem Biophys Res Commun. 1998;252:103-110.
130. Verhaagh S, Schweifer N, Barlow DP, Zwart R. Cloning of the mouse and human solute carrier 22a3 (Slc22a3/SLC22A3) identifies a conserved cluster of three organic cation transporters on mouse chromosome 17 and human 6q26-q27. Genomics. 1999;55:209-218.
131. Wang C, Debiec-Rychter M, Schut H, King C, Haas G. N-acetyltransferase expression and DNA binding of N-hydroxyheterocyclic amines in human prostate epithelium. Carcinogenesis. 1999;20:1591-1595.
132. Wilkinson S, Chodak G. An evaluation of intermediate-dose ketoconazole in hormone refractory prostate cancer. Eur Urol. 2004;45:581-585.
133. Williams J, Martin F, Muir G, Hewer A, Grover P, Phillips D. Metabolic activation of carcinogens and expression of various cytochromes P450 in human prostate tissue. Carcinogenesis. 2000;21:1683-1689.
134. Windmill K, McKinnon R, Zhu X, Gaedigk A, Grant D, McManus M. The role of xenobiotic metabolizing enzymes in arylamine toxicity and Carcinogenesis: functional and localization studies. Mutat Res. 1997;376:153-160.
135. Yamakoshi Y, Kishimoto T, Sugimura K, Kawashima H. Human prostate CYP3A5: identification of a unique 5′-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999;260:676-681.
136. Yao D, Ding S, Burchell B, Wolf C, Friedberg T. Detoxication of vinca alkaloids by human P450 CYP3A4-mediated metabolism: implications for the development of drug resistance. J Pharmacol Exp Ther. 2000;294:387-395.
137. Yokose T, Doy M, Taniguchi T, Shimada T, Kakiki M, Horie T, Matsuzaki Y, Mukai K. Immunohistochemical study of cytochrome P450 2C and 3A in human non-neoplastic and neoplastic tissues. Virchows Arch. 1999;434:401-411.
138. Zeigler-Johnson C, Fiebel T, Walker A, Wang Y, Spangler E, Panossian S, Patacsil M, Aplenc R, Wein A, Malkowicz S, Rebbeck T. CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res. 2004;64:8461-8467.
139. Zhou X, Rahmani R. Preclinical and clinical pharmacology of vinca alkaloids. Drugs. 1992;44(suppl 4):1-16.
140. Zhou X, Zhou-Pan X, Gauthier T, Placidi M, Maurel P, Rahmani R. Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Biochem Pharmacol. 1993;45:853-861.